Clinical Trials Directory

Trials / Unknown

UnknownNCT02260375

MSC Therapy in Liver Transplantation

THIRD-PARTY BONE MARROW-DERIVED MESENCHYMAL STROMAL CELLS TO INDUCE TOLERANCE IN LIVER TRANSPLANT RECIPIENTS

Status
Unknown
Phase
Phase 1
Study type
Interventional
Enrollment
20 (estimated)
Sponsor
Monia Lorini · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The general aim of the present study is to test a cell therapy with third-party allogeneic ex-vivo expanded MSCs as a strategy to induce tolerance in liver transplant recipients. MSCs will be prepared accordingly to established protocols , starting from diagnostic samples of bone marrow aspirates (2-5 mL) or using the remnants in the bag and filter at the end of the bone marrow infusions. From these samples, MSCs will be expanded in GMP approved facilities and used for the present study in patients undergoing liver transplantation.

Conditions

Interventions

TypeNameDescription
BIOLOGICALMesenchymal Stromal Cells

Timeline

Start date
2014-10-01
Primary completion
2024-10-01
Completion
2025-10-01
First posted
2014-10-09
Last updated
2018-04-06

Locations

6 sites across 1 country: Italy

Source: ClinicalTrials.gov record NCT02260375. Inclusion in this directory is not an endorsement.

MSC Therapy in Liver Transplantation (NCT02260375) · Clinical Trials Directory